Dovepress 15. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analysis in the cholesterol and recurrent events (CARE) trial: The CARE Investigators. Circulation. 1998;98:2513–2519. 16. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357. 17. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MCR/BHF Heart Protection Study of cholesterol- lowering with simvastatin in 5,963 people with diabetes: A randomized placebo-controlled trial. Lancet. 2003;361:2005–2016. 18. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihyperten- sive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007. 19. Sever PS, Dahlof B, Poulter NR, et al; for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hyperten- sive subjects who have average or lower-than-average cholesterol con- centratons, in the Anglo-Scandinavian Cardiac Outcome Trial – Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet. 2003;361:1149–1158. 20. Colhoun HM, Betteridge DJ, Durrington PN, et al; The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. Lancet. 2004;364:685–696. 21. American Diabetes Association. Standards of Medical Care in Diabetes – 2009. Diabetes Care. 2009;32 Suppl 1:S13–S61. 22. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiol- ogy Foundation. Diabetes Care. 2008;31:811–822. 23. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106: 2526–2529. 24. Kennedy AG, MacLean CD, Littenberg B, et al. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care. 2005;28:1029–1034. Atherogenic dyslipidemia and diabetes mellitus 25. Nesto RW. LDL cholesterol lowering in Type 2 diabetes: What is the optimum approach. Clin Diabetes. 2008;26:1–6. 26. Staels B, Fruchart J-C. Therapeutic roles of peroxisome proliferator- activated receptor agonists. Diabetes. 2005;54:2460–2470. 27. Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995;96:741–750. 28. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator- activated receptors. Lancet. 1999;354:141–148. 29. Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR-α agonist in patients with atherogenic dyslipidemia or hyper- cholesterolemia. Two randomized controlled trials. JAMA. 2007;297: 1362–1373. 30. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adi- ponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–946. 31. Hardie GD, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell? Annu Rev Biochem. 1998;67:821–855. 32. Fryer LGD, Parbu-Patel A, Carling D. The anti-diabetic drugs rosigli- tazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002;277:25226–25232. 33. Lincoff MA, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patient with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA. 2007;298:1180–1188. 34. The BARI 2D Study Group. Randomized trial of therapies for Type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360: 2503–2515. 35. Peters AA. Clinical relevance of non-HDL cholesterol in patients with diabetes. Clin Diabetes. 2008;26:3–7. 36. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet. 2008;371: 117–125. 37. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trial. Lancet. 2005;366: 1849–1861. Vascular Health and Risk Management Publish your work in this journal Vascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors. Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal Dovepress Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com Dovepress 669